



Hikma acquires six injectable products in Europe

London, 24 June 2016 – Hikma Pharmaceuticals PLC (Hikma) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), (rated Ba1 Moody's / BB+ S&P, both stable), the fast growing multinational pharmaceutical group, announces that it has agreed to acquire a portfolio of six injectable products and their related customer contracts from Pfizer Inc. (NYSE: PFE).

The acquired portfolio includes one anti-infective, one anti-fungal and four oncology products. Five of the products are currently sold across several markets in Europe. The divestiture of these products was mandated by the European Commission as a condition to Pfizer's acquisition of Hospira and the European Commission has announced its approval of Hikma as purchaser of the portfolio.

Said Darwazah, Chairman and Chief Executive Officer of Hikma, said: "This acquisition supports our strategy to strengthen our marketed product portfolio of specialised generic injectables and create new opportunities for growth across our markets."

-- ENDS --

Enquiries

Hikma Pharmaceuticals PLC

Susan Ringdal, VP Corporate Strategy and Investor Relations

+44 (0)20 7399 2760/ +44 7776 477050

Lucinda Baker, Deputy Director of Investor Relations

+44 (0)20 7399 2765/ +44 7818 060211

Zeena Murad, Investor Relations Manager

+44 (0) 20 7399 2768/ +44 7771 665277

FTI Consulting

Ben Atwell/ Matthew Cole

+44 (0)20 3727 1000

About Hikma

Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma operates through three businesses: "Injectables", "Branded" and "Generics", based principally in the United States, the Middle East and North Africa (MENA) and Europe. In 2015, Hikma achieved revenue of \$1,440 million and profit attributable to shareholders of \$252 million.

About Pfizer

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. For more information, please visit us at www.pfizer.com. In addition, to learn more, follow us on Twitter at [@Pfizer](https://twitter.com/Pfizer) and [@Pfizer News](https://twitter.com/PfizerNews), [LinkedIn](https://www.linkedin.com/company/pfizer), [YouTube](https://www.youtube.com/pfizer) and like us on Facebook at [Facebook.com/Pfizer](https://www.facebook.com/Pfizer).